Objective To demonstrate the clinical efficacy of micronized fenofibrate on mildly-moderately elevated LDL-C levels and reduced HDL-C levels.Methods During 1998 - 1999, 2358 patients with type II a, II b and IV hyperlipidemia weremonitored in 16 cities in China. They were treated daily with micronized fenofibrate (micronizedlipanthyl) 200 mg for 8 weeks. Lipid levels before and after the treatment were measured and analyzed.Results Micronized fenofibrate significantly increased HDL-C levels by 12.7%, the effect being inversely correlated to the baseline level of HDL-C. Out of the total patient population, a baseline level of HDL-C <1. 0 mmol/L was found in 837 patients: amongst this group, 510 patients (60. 9%) were observed to have an increase in the level of HDL-C to >1. 0 mmol/L with a mean of 1. 3 mmol/L, after 8-week micronized fenofibrate therapy. Furthermore, the mean LDL-C level decreased by 15. 9% following an 8-week treatment of micronized fenofibrate, an effect positively correlated to the ba Objective To demonstrate the clinical efficacy of micronized fenofibrate on mildly-moderately elevated LDL-C levels and reduced HDL-C levels. Methods during 1998 - 1999, 2358 patients with type II a, II b and IV hyperlipidemia were monitored in 16 cities in China. They were treated daily with micronized fenofibrate (micronized lipidyl) 200 mg for 8 weeks. Lipid levels before and after the treatment were both measured and analyzed. Results Micronized fenofibrate significantly increased HDL-C levels by 12.7%, the effect being inversely correlated at the baseline level of HDL-C. Out of the total patient population, a baseline level of HDL-C <1.0 mmol / L was found in 837 patients: amongst this group, 510 patients (60.9%) were observed to have an increase at the level of HDL-C to> 1.0 mmol / L with a mean of 1.3 mmol / L after 8-week micronized fenofibrate therapy. Further, the mean LDL-C level decreased by 15. 9% following an 8-week treatment of micronized fenofibrate, an effect positively co rrelated to the ba